Jefferies Group Analysts Give GlaxoSmithKline (GSK) a GBX 1,600 Price Target

GlaxoSmithKline (LON:GSK) received a GBX 1,600 ($22.91) target price from investment analysts at Jefferies Group in a research note issued to investors on Friday, April 13th. The brokerage currently has a “buy” rating on the stock. Jefferies Group’s target price indicates a potential upside of 11.83% from the company’s previous close.

Several other research analysts have also recently issued reports on the company. Kepler Capital Markets reaffirmed a “hold” rating on shares of GlaxoSmithKline in a report on Thursday, April 12th. UBS set a GBX 1,600 ($22.91) price target on GlaxoSmithKline and gave the company a “buy” rating in a report on Thursday, April 5th. Credit Suisse Group upped their price target on GlaxoSmithKline from GBX 1,300 ($18.61) to GBX 1,450 ($20.76) and gave the company a “neutral” rating in a report on Tuesday, April 3rd. Morgan Stanley set a GBX 1,400 ($20.05) target price on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Tuesday, April 3rd. Finally, Berenberg Bank boosted their target price on shares of GlaxoSmithKline from GBX 1,705 ($24.41) to GBX 1,780 ($25.49) and gave the company a “buy” rating in a research note on Wednesday, March 28th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of GBX 1,554.32 ($22.26).

How to Become a New Pot Stock Millionaire

GSK opened at GBX 1,430.80 ($20.49) on Friday. GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($17.69) and a 1-year high of GBX 1,724.50 ($24.69).

In other GlaxoSmithKline news, insider Victoria Whyte sold 5,199 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of GBX 1,295 ($18.54), for a total transaction of £67,327.05 ($96,401.85). Also, insider Patrick Vallance sold 14,022 shares of the company’s stock in a transaction dated Monday, February 19th. The shares were sold at an average price of GBX 1,318 ($18.87), for a total transaction of £184,809.96 ($264,619.07). Over the last 90 days, insiders have acquired 589 shares of company stock valued at $754,828 and have sold 23,765 shares valued at $31,152,709.

WARNING: This news story was originally published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://weekherald.com/2018/04/20/glaxosmithkline-gsk-pt-set-at-gbx-1600-by-jefferies-group.html.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply